BiX Secures KRW 300 Million Pre-A Investment from Shinhan Venture Investment

A later company profile reports that BiX secured KRW 300 million in Pre-A funding from Shinhan Venture Investment in November 2025. The investment followed the company's initial seed round and provided additional resources for product development and clinical validation.

BiX is developing a multimodal AI platform that combines CT images with longitudinal and clinical information to detect subtle signs associated with pancreatic and other abdominal cancers. Its proof-of-concept pancreatic-cancer model reached 95% diagnostic accuracy.

The funding supports refinement of DeepScout, collaboration with medical institutions, integration with hospital PACS workflows, and preparation for Korean and international medical-device authorization. BiX plans to expand the technology from pancreatic cancer to liver, biliary-tract, and broader abdominal-cancer applications.